Archer Materials Confirms Suitability of Silicon Foundation for Potassium-Sensing Biochip Device

Small Caps

Oct 29

Initial data from first-stage testing of Archer Materials’ (ASX: AXE) blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579126369"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579126369\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579126369?lang=en_US&edition=fundamental","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/Archer-Materials-ASX-AXE-Suitability-Silicon-Foundation-Potassium-Sensing-Biochip-Device.jpg","is_english":true,"pubTime":"2025-10-29 08:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579126369","market":"nz","top_or_hot":-1,"title":"Archer Materials Confirms Suitability of Silicon Foundation for Potassium-Sensing Biochip Device","media":"Small Caps","content":"<div>\n<p>Initial data from first-stage testing of Archer Materials’ (ASX: AXE) blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic ...</p>\n\n<a href=\"https://smallcaps.com.au/archer-materials-suitability-silicon-foundation-potassium-sensing-biochip-device/\">Source Link</a>\n\n</div>\n","source":"smallcap_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Archer Materials Confirms Suitability of Silicon Foundation for Potassium-Sensing Biochip Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcher Materials Confirms Suitability of Silicon Foundation for Potassium-Sensing Biochip Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 08:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://smallcaps.com.au/archer-materials-suitability-silicon-foundation-potassium-sensing-biochip-device/><strong>Small Caps</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Initial data from first-stage testing of Archer Materials’ (ASX: AXE) blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic ...</p>\n\n<a href=\"https://smallcaps.com.au/archer-materials-suitability-silicon-foundation-potassium-sensing-biochip-device/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7069","symbol_name":"半导体产品","start_time":0,"source_url":"https://smallcaps.com.au/archer-materials-suitability-silicon-foundation-potassium-sensing-biochip-device/","article_id":"2579126369","we_media_id":null,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/Archer-Materials-ASX-AXE-Suitability-Silicon-Foundation-Potassium-Sensing-Biochip-Device.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/archer-materials-suitability-silicon-foundation-potassium-sensing-biochip-device/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579126369","pubTimestamp":1761697511,"columns":[],"sourceInfo":{"source_id":"smallcap_stock","name":"Small Caps"},"weMediaInfo":null,"summary":"Initial data from first-stage testing of Archer Materials’  blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic applications.Archer expects the findings to de-risk its supply chain, reduce unit costs, and accelerate the pathway towards manufacture and commercialisation.The company is now on track to finalise a working prototype and progress toward clinical trials in the new year as it moves towards project validation and commercial readiness.Archer has partnered with the Interuniversity Microelectronics Centre  in Belgium to develop the Biochip and blood potassium sensor, with IMEC leveraging its semiconductor technology and expertise to enable the use of graphene and silicon-based devices during testing.“Leveraging IMEC’s world-class silicon fabrication capabilities alongside our proprietary sensor functionalisation methods means we are in a position to […] expand our future applications in point-of-care and ","collect":0,"end_time":0,"defaultTopTitle":"smallcaps.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7069":"半导体产品","ARKG":"ARK Genomic Revolution ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","AXE.AU":"ARCHER MATERIALS LTD","BK4544":"ARK ETF合集"},"translate_title":"Archer Materials确认硅基础适用于钾传感生物芯片设备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXE.AU":1,"ARKG":1.5},"content_text":"Initial data from first-stage testing of Archer Materials’ (ASX: AXE) blood potassium graphene Biochip project have shown the technology suitable for silicon for point-of-care and at-home diagnostic applications.\nArcher expects the findings to de-risk its supply chain, reduce unit costs, and accelerate the pathway towards manufacture and commercialisation.\nThe company is now on track to finalise a working prototype and progress toward clinical trials in the new year as it moves towards project validation and commercial readiness.\nIMEC Development Partnership\nArcher has partnered with the Interuniversity Microelectronics Centre (IMEC) in Belgium to develop the Biochip and blood potassium sensor, with IMEC leveraging its semiconductor technology and expertise to enable the use of graphene and silicon-based devices during testing.\nFirst results have shown the silicon devices can meet blood potassium accuracy requirements, matching Archer’s graphene field effect transistor (gFET) performance as well as the clinical CLIA standard.\nTesting demonstrated strong potential for a high-performance, scalable, and clinically-compliant biosensor platform—the first major step in accelerating the Biochip’s development and commercialisation.\nIMEC has fabricated three Biochip-based sensor devices using its established silicon wafer processing technology which it then modified, functionalised, and tested using Archer’s proprietary methods to assess their potassium-sensing performance.\nThe devices have delivered shorter conditioning and stabilisation times of around 30 minutes, which is a significant improvement on current gFET lab testing results.\nPathway to Commercialisation\nArcher chief executive officer Dr Simon Ruffell said the initial data marked an important milestone for the company’s Biochip program.\n“Demonstrating that our technology can be built using silicon rather than graphene can significantly broaden our manufacturing options and strengthen our path to commercialisation,” he said.\n“Leveraging IMEC’s world-class silicon fabrication capabilities alongside our proprietary sensor functionalisation methods means we are in a position to […] expand our future applications in point-of-care and at-home diagnostics.”\nDr Ruffell said the company would now begin planning the regulatory approvals pathway for the Biochip project, and work towards a new major project with IMEC focused on potassium sensing for chronic kidney disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}